Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway

about

Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway

Item

http://www.wikidata.org/entity/Q41917874

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Loss of AMPK activation promot ...... ough an HSF1-dependent pathway

@en

type

Item

label

Loss of AMPK activation promot ...... ough an HSF1-dependent pathway

@en

prefLabel

Loss of AMPK activation promot ...... ough an HSF1-dependent pathway

@en

P1476

Loss of AMPK activation promot ...... ough an HSF1-dependent pathway

@en

P2093

Bin Yan

http://www.w3.org/2001/XMLSchema#string

Cancan Zhou

http://www.w3.org/2001/XMLSchema#string

Jie Li

http://www.w3.org/2001/XMLSchema#string

Jiguang Ma

http://www.w3.org/2001/XMLSchema#string

Junyu Cao

http://www.w3.org/2001/XMLSchema#string

Ke Chen

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Liankang Sun

http://www.w3.org/2001/XMLSchema#string

Meng Lei

http://www.w3.org/2001/XMLSchema#string

Qingyong Ma

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian AMP-activated protein kinase subfamily

Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression

AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function

Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma

Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P304

1475-1492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/1878-0261.12116

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28783244

http://www.w3.org/2001/XMLSchema#string

P932

5623818

http://www.w3.org/2001/XMLSchema#string